The HIV Epidemic in the United States – Epidemiological Projections and Public Economic Impact of Achieving Zero Transmission Goals
Open Access
- 1 October 2025
- journal article
- research article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 17, 755-769
Abstract
Background: The United States (US) HIV/AIDS strategy has targeted a 90% reduction in HIV infections by 2030. Whilst progress has been made in US HIV policy, the persistence of nearly 32,000 new infections annually highlights substantial barriers that still hinder effective treatment and the achievement of national targets. While the humanistic burden of HIV is well documented, there are broader economic effects on employment, disability and retirement. The objective of this study is to evaluate these economic gains when improving various HIV policies. Methodology: This analysis adapts a published Markov model assessing the role of six key policy parameters related to diagnosis, pre-exposure prophylaxis (PrEP) uptake, treatment initiation, and treatment as prevention (TasP) on the HIV epidemic in the US. Improvements in these parameters were explored to estimate averted HIV infections over 50 years and, subsequently, the feasibility of achieving the 2030 target of a 90% reduction in HIV incidence. A fiscal economic framework was also applied, linking HIV cases and policy targets to productivity, tax revenue, transfer benefits, and healthcare costs incurred by the US government. Results: Results were calculated for the general US population and for men who have sex with men (MSM), a subgroup experiencing a high HIV burden. For the general US population, policy improvements led to an average of 5,324 averted HIV infections annually over the 50-year horizon, corresponding to a total net annual fiscal gain of $397 million or $74,511 per averted infection. For the MSM subgroup, 911 infections were averted annually resulting in a net fiscal gain of $96 million, or $105,031 per averted infection. Conclusion: This analysis demonstrates that the benefits of HIV policy are not limited to the healthcare setting and show how initial investments provide long-term benefits by preventing HIV transmission and the associated impact on individuals’ labor market outcomes. While relying on assumptions and projections that may not capture all real-word complexities, fiscal analyses can provide a useful tool for policy evaluation that facilitate a holistic assessment of the wider costs and benefits that fall on governments as well as benefits of achieving policy targets.Keywords
This publication has 44 references indexed in Scilit:
- Excess HIV Infections and Costs Associated With Reductions in HIV Prevention Services in the USJAMA Network Open, 2025
- Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure ProphylaxisJAMA Network Open, 2023
- The US Medicaid ProgramJAMA, 2022
- Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016JAMA Network Open, 2020
- Regional Disparities in Qualified Health Plans’ Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United StatesJAMA Network Open, 2020
- A Scoping Review of Employment and HIVAIDS and Behavior, 2020
- Trends in HIV Testing Among US Adults, Aged 18–64 Years, 2011–2017AIDS and Behavior, 2019
- Sustainability of public finances: inclusion of unrelated medical cost only part of the storyThe European Journal of Health Economics, 2019
- Unemployment, health, and education of HIV-infected males in GermanyInternational Journal of Public Health, 2015
- Enhancing Labour Force Participation for People Living with HIV: A Multi-Perspective Summary of the Research EvidenceAIDS and Behavior, 2011